Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track AIM with free AI briefings, catalyst countdowns, and dilution alerts.

AIM · AIM ImmunoTech Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$6.9M Cash on Hand
5.5mo Cash Runway
2.5% Short Interest
$4.25 Analyst Target (2)
Follow AIM by email Get an email when AIM reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about AIM, unsubscribe in one click. Privacy

📣 What AIM Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Rintatolimod Chronic Fatigue Syndrome Phase 3 · NCT00215800 Completed
αDC1 Vaccine Ovarian Cancer Phase 2 · NCT07634094 Not yet recruiting
Alferon LDO HIV Infections Phase 2 · NCT00215852 Terminated
Recombinant Interferon Alfa-2b Prostate Adenocarcinoma Phase 2 · NCT03899987 Active not recruiting
Trivalent Live-Attenuated Influenza Vaccine Influenza, Human Phase 1/2 · NCT01591473 Terminated
Aspirin Prostate Adenocarcinoma Phase 2 · NCT03899987 Active not recruiting
Creatine Kinase M-Type Cancer of Ovary Phase 1/2 · NCT02432378 Withdrawn

Also used in these trials (approved or third-party drugs, not AIM's own candidates): Pembrolizumab, Paclitaxel, Durvalumab, Cisplatin, Celecoxib.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

AIM holds $6.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $3.8M/quarter from operations, an estimated runway of 5.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 80 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AIM files for a raise →

👥 Who Owns AIM

Insiders 5% Other 5%+ holders 4.5% Institutions 2.5% Public and other holders 88%
HolderTypeShares% of sharesAs of
Orca Capital AG 5%+ holder (13G) 1,793,999 4.49% 2026-05-07
Jane Street Group, LLC Institution (13F) 603,689 1.51% 2026-09-30
William M Mitchell
Director
Insider 522,103 1.31% 2025-04-21
Peter W III Rodino
COO, Secretary, Gen. Counsel · +100,000 options
Insider 401,762 1.01% 2025-04-04
Stewart Appelrouth
Director
Insider 388,729 0.97% 2024-12-31
Thomas K Equels
CEO & President, Director · +350,025 options
Insider 328,095 0.82% 2026-11-11
Nancy Bryan
Director
Insider 291,882 0.73% 2025-03-14
Vanguard Fiduciary Trust Co Institution (13F) 241,835 0.61% 2026-09-30
UBS Group AG Institution (13F) 58,544 0.15% 2026-09-30
Geode Capital Management, LLC Institution (13F) 45,321 0.11% 2026-09-30
Ted D Kellner
Director
Insider 37,205 0.09% 2025-07-17
Citigroup Inc. Institution (13F) 37,079 0.09% 2026-09-30

Share count 39,919,844 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-11
filed 2026-11-13
Equels Thomas K
Purchase (P) 35,000 $0.15 328,095
2026-11-10
filed 2026-11-12
Equels Thomas K
Purchase (P) 39,000 $0.14 293,095
2026-11-09
filed 2026-11-10
Equels Thomas K
Purchase (P) 31,298 $0.16 254,095
2026-11-06
filed 2026-11-09
Equels Thomas K
Purchase (P) 12,751 $0.16 222,797
2026-10-23
filed 2026-10-26
Equels Thomas K
Purchase (P) 31,675 $0.16 189,747

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full AIM picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AIM and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.